All In Biotech

Drug Trial Radar · NCT03075410

First Time in Human (FTIH) Safety and Pharmacokinetics (PK) Study of GSK3036656 in Healthy Subjects

A Double Blind, Placebo-controlled First Time in Human Study to Evaluate the Safety, Tolerability and Pharmacokinetics of Single and Repeat Doses of GSK3036656 in Healthy Adult Volunteers

Last checked: Nov 20, 2026Latest source record: Apr 19, 2019 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registry

Status

Completed

Enrollment

30

Actual

Start

Apr 2, 2017

Primary completion

Aug 4, 2017

Study completion Aug 4, 2017

Sponsor

Lead sponsor
GlaxoSmithKlineGSK (GSK)
Sponsor type
Industry
First posted
Mar 9, 2017

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Single group
Masking
Double (participant, investigator)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 55 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

GSK3036656 is being developed by GSK for the treatment of tuberculosis (TB). This is the FTIH study for GSK3036656 to evaluate the safety, tolerability and PK of single ascending and repeat oral doses of GSK3036656 in healthy adult subjects. The results of this study are intended to be used to identify appropriate and well-tolerated doses of GSK3036656 to be used in further studies. A food effect assessment will also be undertaken to investigate the influence of food on the PK of GSK3036656. The study will be conducted in two parts: Part A (single dose) and Part B (repeat dose). Up to two cohorts will be included in Part A. 9 healthy adult subjects will be included in each cohort. Each cohort will participate in up to 4 treatment (dosing) periods including a food effect treatment period. During each treatment period, GSK3036656 will be administered to 6 subjects and placebo will be administered to 3 subjects. The starting dose in Part A will be 5 milligrams (mg), and the maximum dose will be 1500 mg. The two cohorts in Part A will be dosed sequentially (i.e., dosing in Cohort 2 starts after dosing in Cohort 1 is completed). Initially, there will be a 14 day wash out period for individual subjects between each dose level. Study progression to Part B from Part A will be based on an acceptable safety, tolerability and PK profile in Part A. Part B will comprise up to 4 cohorts (Cohorts 3, 4, 5, and 6) each containing 10 (8 active: 2 placebo) healthy adult subjects to examine the safety, tolerability and PK of a repeated daily dose of GSK3036656 over a period of up to 14 days. Appropriate doses and dose regimens for Part B will be selected based on available safety, tolerability and PK data from Part A and/or any preceding repeat dose cohorts from Part B. Dividing the total daily dose into 2 or 3 smaller doses may be done in both Part A and Part B. Up to 18 subjects will be enrolled into Part A and up to 40 subjects will be enrolled into Part B. The total duration of the study for each subject recruited into Part A and Part B will be approximately 12 weeks and 8 weeks, respectively.

Conditions

  • Tuberculosis

Interventions

  • GSK3036656Drug

    GSK3036656 is available as capsules (for oral administration) containing 5 mg, 25 mg or 100 mg of GSK3036656 as free base equivalent.

  • PlaceboDrug

    Placebo is a matching capsule containing Avicel PH (Suitable for Pharmaceutical Use) 102, for oral administration.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of Participants With Non-serious Adverse Events (nSAE) and Serious Adverse Events (SAEs) for Part ATime frame: Up to 12 weeks
  2. Number of Participants With nSAE and SAEs for Part BTime frame: Up to 8 weeks
  3. Number of Participants With Abnormal Electrocardiogram (ECG) Findings for Part ATime frame: Up to 6 weeks
  4. Number of Subjects With Clinically Relevant Changes in ECG in Part BTime frame: Up to 8 weeks
  5. Number of Participants With Abnormal Cardiac Telemetry Findings for Part ATime frame: 25 hours for each period
  6. Number of Participants With Abnormal Cardiac Telemetry Findings for Part BTime frame: 25 hours for each period
  7. Number of Participants With Vital Sign Parameters Systolic Blood Pressure (SBP) and Diastolic Blood Pressure (DBP) of Potential Clinical Importance (PCI) for Part ATime frame: Up to 6 weeks
  8. Number of Participants With Vital Sign Parameters SBP and DBP of PCI for Part BTime frame: Up to 8 weeks
  9. Number of Participants With Vital Sign Parameter Heart Rate of PCI for Part ATime frame: Up to 6 weeks
  10. Number of Participants With Vital Sign Parameter Heart Rate of PCI for Part BTime frame: Up to 8 weeks
  11. Number of Participants With Vital Sign Parameter Temperature of PCI for Part ATime frame: Up to 6 weeks
  12. Number of Participants With Vital Sign Parameter Temperature of PCI for Part BTime frame: Up to 8 weeks
  13. Number of Participants With Clinical Chemistry Parameters of PCI for Part ATime frame: Up to 12 weeks
  14. Number of Participants With Clinical Chemistry Parameters of PCI for Part BTime frame: Up to 8 weeks
  15. Number of Participants With Hematology Parameters of PCI for Part ATime frame: Up to 12 weeks
  16. Number of Participants With Hematology Parameters of PCI for Part BTime frame: Up to 8 weeks
  17. Number of Participants With Abnormal Urinalysis Parameters for Part ATime frame: Up to 72 hours post-dose
  18. Urine Potential of Hydrogen (pH) Analysis by Dipstick Method for Part ATime frame: Up to 72 hours post-dose
  19. Number of Participants With Abnormal Urinalysis Parameters for Part BTime frame: Up to 8 weeks
  20. Urine pH Analysis by Dipstick Method for Part BTime frame: Up to 8 weeks
  21. Area Under the Plasma Concentration-time Curve (AUC) From Time Zero to the Time of Last Quantifiable Concentration (AUC[0-t]) Following Single Dose Administration of GSK3036656 for Part ATime frame: Pre-dose and at 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 8, 12, 15, 24, 36, 48 and 72 hour post-dose on Day 1 in each period
  22. AUC From Time Zero Extrapolated to Infinite Time (AUC[0-infinity]) of GSK3036656 Following Single Dose Administration for Part ATime frame: Pre-dose and at 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 8, 12, 15, 24, 36, 48 and 72 hour post-dose on Day 1 in each period
  23. Maximum Observed Plasma Drug Concentration (Cmax) of GSK3036656 Following Single Dose Administration for Part ATime frame: Pre-dose and at 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 8, 12, 15, 24, 36, 48 and 72 hour post-dose on Day 1 in each period
  24. Time to Maximum Observed Plasma Drug Concentration (Tmax) of GSK3036656 Following Single Dose Administration for Part ATime frame: Pre-dose and at 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 8, 12, 15, 24, 36, 48 and 72 hour post-dose on Day 1 in each period
  25. Apparent Terminal Half-life (t1/2) of GSK3036656 Following Single Dose Administration for Part ATime frame: Pre-dose and at 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 8, 12, 15, 24, 36, 48 and 72 hour post-dose on Day 1 in each period
  26. AUC[0-t] Following Repeated Dose Administration of GSK3036656 for Part BTime frame: Pre-dose and at 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 8, 12, 15, 24, 36, 48 and 72 hour post-dose on Day 1
  27. AUC From Time Zero During a Dosing Interval of Duration Tau (AUC[0-tau]) of GSK3036656 Following Repeated Dose Administration for Part BTime frame: Pre-dose and at 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 8, 12, 15, 24, 36, 48 and 72 hour post-dose on Day 14
  28. Cmax of GSK3036656 Following Repeated Dose Administration for Part BTime frame: Pre-dose and at 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 8, 12, 15, 24, 36, 48 and 72 hour post-dose on Day 1; at pre-dose and at 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 8, 12, 15, 24, 36, 48 and 72 hour post-dose on Day 14; and at pre-dose on Days 12 and 13
  29. Tmax of GSK3036656 Following Repeat Dose Administration for Part BTime frame: Pre-dose and at 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 8, 12, 15, 24, 36, 48 and 72 hour post-dose on Day 1; at pre-dose and at 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 8, 12, 15, 24, 36, 48 and 72 hour post-dose on Day 14; and at pre-dose on Days 12 and 13
  30. t1/2 of GSK3036656 Following Repeated Dose Administration for Part BTime frame: Pre-dose and at 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 8, 12, 15, 24, 36, 48 and 72 hour post-dose on Day 14.

Locations

2 sites in 1 country. Site status is shown where the registry gives one.

  • GSK Investigational Site

    London, United Kingdom

  • GSK Investigational Site

    London, United Kingdom

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.